Introduced stereochemical control as a new platform feature, potentially offering customers superior therapeutic potency and purity compared to traditional methods.Stabilized the heritage small-molecule biocatalysis business, returning it to healthy profit margins to provide a self-sustaining financial foundation for RNA innovation.Surpassed commercial goals by signing three CDMO agreements with Bachem, Nitto Avecia, and Axolabs to address limitations in standard solid-phase chemical processes.Achieved a cr ...